Despite the exciting clinical progression of PROTAC-based therapies, much of the fundamental biology and chemistry in the field is still unknown, with many discovery and development challenges still holding back the translation of robust candidates into the clinic.

The Inaugural Targeted Protein Degradation Europe 2020, as your forward looking and industry dedicated platform, will be bringing together key European and international experts in the field of protein degradation to capture the most pioneering data, thought provoking insights and practical lessons learned, enabling you to maximise the therapeutic window of your TPD strategy.

Built with large pharma and biotech insight, Targeted Protein Degradation Europe 2020 focuses on expanding the fundamental understanding of protein degradation in order to validate the next generation of druggable targets, optimise drug-like properties and leverage degradation pathways beyond the ubiquitin-proteasome system to accelerate robust translation of TPD candidates for clinical trials in oncology and neurodegenerative diseases.

View the full event guide for further details on speakers, content and how to join those who are re-defining the targeted protein degradation field.